Net sales for the first quarter were 69,007 million yen (YoY 23.1% increase), but operating income was 10,695 million yen (down 9.7% YoY) and net income attributable to owners of the parent was 7,571 million yen (down 12.1% YoY) despite revenue growth. By segment, Functional Chemicals performed well, Pharmaceuticals\/Medical\/Health declined, and Fine Chemicals posted a substantial increase, with Other segments flat. Full-year guidance remained unchanged. Treasury stock acquisition and cancellation are planned.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4403","jir_company_name":"\u65e5\u6cb9\u682a\u5f0f\u4f1a\u793e","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-08-05","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4403-20260805-03.pdf","jir_short_summary":"Net sales for the first quarter were 69,007 million yen (YoY 23.1% increase), but operating income was 10,695 million yen (down 9.7% YoY) and net income attributable to owners of the parent was 7,571 million yen (down 12.1% YoY) despite revenue growth. By segment, Functional Chemicals performed well, Pharmaceuticals\/Medical\/Health declined, and Fine Chemicals posted a substantial increase, with Other segments flat. Full-year guidance remained unchanged. Treasury stock acquisition and cancellation are planned.","jir_summary":"### Overview of results\nFor the first quarter of the fiscal year ending March 2027, net sales rose sharply year over year, while operating income, ordinary income, and net income attributable to owners of the parent declined. By segment, Functional Chemicals remained solid, demand for Pharmaceuticals\/Medical\/Health decreased, and Fine Chemicals recorded a substantial increase. Against the backdrop of fluctuations in raw material prices and supply-demand conditions, global market uncertainty continues. Full-year guidance was maintained at the time of the release.\n\n### Outlook and capital policy\nFull-year earnings guidance is unchanged at this stage. The policy of acquiring and cancelling treasury stock is noted as a key additional detail, with the aim of stable shareholder returns under the NOF VISION 2030 Stage III, targeting a total_Returned_Value ratio of over 70%. The financial position shows total assets declining while the equity ratio rose. Ongoing monitoring of crude oil-derived raw materials supply stability and crude fuel price trends continues.","jir_financial_highlights":"Net sales: 69,007\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd423.1\uff05\u5897)\nOperating income: 10,695\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd4\u25b39.7\uff05)\nOrdinary income: 11,505\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd4\u25b36.3\uff05)\nNet income attributable to owners of the parent (quarter): 7,571\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd4\u25b312.1\uff05)\nSegment - Functional Chemicals: 39,177\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd48.8\uff05\u5897)\nSegment - Pharmaceuticals\/Medical\/Health: 11,244\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd417.9\uff05\u6e1b)\nSegment - Fine Chemicals: 18,411\u767e\u4e07\u5186 (\u524d\u5e74\u540c\u671f\u6bd4197.8\uff05\u5897)\nEnding treasury stock: 11,789,730\u682a (\u524d\u5e74\u540c\u671f\u6bd4)\nTotal assets: 382,306\u767e\u4e07\u5186 (\u524d\u671f\u6bd4\u25b316,861\u767e\u4e07\u5186)\nEquity ratio: 76.7\uff05 (\u524d\u671f\u6bd42.7\u30dd\u30a4\u30f3\u30c8\u4e0a\u6607)","jir_category":"","jir_hashtags":"#\u65e5OilCompany, #FinancialResults, #JapanStocks","jir_key_figures":"Net sales: 69,007\u767e\u4e07\u5186\uff08\u524d\u5e74\u540c\u671f\u6bd423.1\uff05\u5897\uff09\nOperating income: 10,695\u767e\u4e07\u5186\uff08\u524d\u5e74\u540c\u671f\u6bd4\u25b39.7\uff05\uff09\nNet income attributable to owners of the parent (quarter): 7,571\u767e\u4e07\u5186\uff08\u524d\u5e74\u540c\u671f\u6bd4\u25b312.1\uff05\uff09","jir_meta_title":"\u3010\u65e5Oil Company\u3011Q1 FY2027 Financial Results\uff5cNet sales 69,007 million yen, Net income 7,571 million yen","jir_meta_description":"Key points from NOF's Q1 FY2027 financial results: net sales up 23.1% YoY, operating income down, Pharmaceuticals\/Medical\/Health surged, outlook and shareholder return policy explained.","jir_og_title":"\u65e5Oil Company Q1 Results\uff5cSales increase, but profits decrease","jir_og_description":"Summary of NOF's Q1 results: sales rose while profits declined. Segment trends and future shareholder return policy are summarized.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7684,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-94809","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n